Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients

Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients

To assess the efficacy of subcutaneous (sc) belimumab (BLM) by the application of SLE-DAS in a monocentric SLE cohort. We evaluated SLE patients treated with sc BLM from March 2019. Disease activity has been assessed by SLEDAI-2k, SLE-DAS and PGA (Physician Global Assessment) in all the established...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental rheumatology 2024-07, Vol.42 (7), p.1491
Hauptverfasser: Ceccarelli, Fulvia, Picciariello, Licia, Natalucci, Francesco, Moretti, Valeria, Spinelli, Francesca Romana, Alessandri, Cristiano, Conti, Fabrizio
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 7
container_start_page 1491
container_title Clinical and experimental rheumatology
container_volume 42
creator Ceccarelli, Fulvia
Picciariello, Licia
Natalucci, Francesco
Moretti, Valeria
Spinelli, Francesca Romana
Alessandri, Cristiano
Conti, Fabrizio
description To assess the efficacy of subcutaneous (sc) belimumab (BLM) by the application of SLE-DAS in a monocentric SLE cohort. We evaluated SLE patients treated with sc BLM from March 2019. Disease activity has been assessed by SLEDAI-2k, SLE-DAS and PGA (Physician Global Assessment) in all the established time-points [baseline (T0), after 1 (T1), 3 (T3), 6 (T6) and 12 (T12) months]. Furthermore, we applied and compared the achievement of remission according to SLE-DAS values (SLEDAS ≤2.08 + PDN ≤5mg/daily) and DORIS definition (clinical SLEDAI- 2k=0 + PGA
doi_str_mv 10.55563/clinexprheumatol/l5976o
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3063460056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3063460056</sourcerecordid><originalsourceid>FETCH-LOGICAL-c190t-13ba0dd0ab27ad8e7c83c4933164e7f2480b95c20d3e87c2381cd9a5d7aa068b3</originalsourceid><addsrcrecordid>eNpdkE1PwzAMhiMEYmPwF1COXMrSpkmT4zTGhzSJw0DarUpTVytKm1KnEvv3dGxw4GRZ8uPXfgihMbsXQkg-t65u4avrdzA0Jng3d0Jn0p-RaSw0j5hW23MyZVwnkRJyOyFXiB-MJVLI7JJMuFKx1qmakmHRda62JtS-pb6im_UqelhsaPDUIAIixaGwQzAt-AFpAa5uxsiCQlWNmN3TuqWGWr_zfTgswD0GaGpL3dCNAPT7sIPDjTh23ZgDbcBrclEZh3BzqjPy_rh6Wz5H69enl-ViHdlYsxDFvDCsLJkpksyUCjKruE0157FMIauSVLFCC5uwkoPKbMJVbEttRJkZw6Qq-IzcHfd2vf8cAEPe1GjBueM7OWeSp5KxUemMqOOo7T1iD1Xe9XVj-n0es_xHev5fen6UPqK3p5ShaKD8A38t82-l9IcZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3063460056</pqid></control><display><type>article</type><title>Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients</title><source>Alma/SFX Local Collection</source><creator>Ceccarelli, Fulvia ; Picciariello, Licia ; Natalucci, Francesco ; Moretti, Valeria ; Spinelli, Francesca Romana ; Alessandri, Cristiano ; Conti, Fabrizio</creator><creatorcontrib>Ceccarelli, Fulvia ; Picciariello, Licia ; Natalucci, Francesco ; Moretti, Valeria ; Spinelli, Francesca Romana ; Alessandri, Cristiano ; Conti, Fabrizio</creatorcontrib><description>To assess the efficacy of subcutaneous (sc) belimumab (BLM) by the application of SLE-DAS in a monocentric SLE cohort. We evaluated SLE patients treated with sc BLM from March 2019. Disease activity has been assessed by SLEDAI-2k, SLE-DAS and PGA (Physician Global Assessment) in all the established time-points [baseline (T0), after 1 (T1), 3 (T3), 6 (T6) and 12 (T12) months]. Furthermore, we applied and compared the achievement of remission according to SLE-DAS values (SLEDAS ≤2.08 + PDN ≤5mg/daily) and DORIS definition (clinical SLEDAI- 2k=0 + PGA&lt;0.5 + antimalarial treatment, PDN≤5mg/daily, stable immunosuppressive treatment). We enrolled 86 patients [M/F 5/81, median age 48 years (IQR 17.5), median disease duration 166 months (IQR 216)]. At baseline, median values of SLEDA-2k and SLE-DAS were 6 (IQR 4) and 5.77 (IQR 4.33), respectively, and they significantly correlated (r=0.719, CI 95% 0.586-0.815, p&lt;0.0001). Median duration of treatment was 14 months (IQR 20). We found a significant reduction of SLEDAI-2k and SLE-DAS already at T1, maintained in the subsequent time-points (p&lt;0.0001). At T12, a remission state was achieved by 60.4% of patients according to SLE-DAS definition and by 62.3% according to the DORIS definition. Both definitions of remission have demonstrated an agreement of 84%, with a Cohen's kappa equal to 0.6. In this study we applied SLE-DAS to assess the efficacy of sc BLM, by analysing its over-time changes and by comparing its performance with SLEDAI-2k. Indeed, our results suggest the usefulness of this new activity index in a real-life setting.</description><identifier>ISSN: 0392-856X</identifier><identifier>ISSN: 1593-098X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>DOI: 10.55563/clinexprheumatol/l5976o</identifier><identifier>PMID: 38819948</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical and experimental rheumatology, 2024-07, Vol.42 (7), p.1491</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38819948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ceccarelli, Fulvia</creatorcontrib><creatorcontrib>Picciariello, Licia</creatorcontrib><creatorcontrib>Natalucci, Francesco</creatorcontrib><creatorcontrib>Moretti, Valeria</creatorcontrib><creatorcontrib>Spinelli, Francesca Romana</creatorcontrib><creatorcontrib>Alessandri, Cristiano</creatorcontrib><creatorcontrib>Conti, Fabrizio</creatorcontrib><title>Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>To assess the efficacy of subcutaneous (sc) belimumab (BLM) by the application of SLE-DAS in a monocentric SLE cohort. We evaluated SLE patients treated with sc BLM from March 2019. Disease activity has been assessed by SLEDAI-2k, SLE-DAS and PGA (Physician Global Assessment) in all the established time-points [baseline (T0), after 1 (T1), 3 (T3), 6 (T6) and 12 (T12) months]. Furthermore, we applied and compared the achievement of remission according to SLE-DAS values (SLEDAS ≤2.08 + PDN ≤5mg/daily) and DORIS definition (clinical SLEDAI- 2k=0 + PGA&lt;0.5 + antimalarial treatment, PDN≤5mg/daily, stable immunosuppressive treatment). We enrolled 86 patients [M/F 5/81, median age 48 years (IQR 17.5), median disease duration 166 months (IQR 216)]. At baseline, median values of SLEDA-2k and SLE-DAS were 6 (IQR 4) and 5.77 (IQR 4.33), respectively, and they significantly correlated (r=0.719, CI 95% 0.586-0.815, p&lt;0.0001). Median duration of treatment was 14 months (IQR 20). We found a significant reduction of SLEDAI-2k and SLE-DAS already at T1, maintained in the subsequent time-points (p&lt;0.0001). At T12, a remission state was achieved by 60.4% of patients according to SLE-DAS definition and by 62.3% according to the DORIS definition. Both definitions of remission have demonstrated an agreement of 84%, with a Cohen's kappa equal to 0.6. In this study we applied SLE-DAS to assess the efficacy of sc BLM, by analysing its over-time changes and by comparing its performance with SLEDAI-2k. Indeed, our results suggest the usefulness of this new activity index in a real-life setting.</description><issn>0392-856X</issn><issn>1593-098X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkE1PwzAMhiMEYmPwF1COXMrSpkmT4zTGhzSJw0DarUpTVytKm1KnEvv3dGxw4GRZ8uPXfgihMbsXQkg-t65u4avrdzA0Jng3d0Jn0p-RaSw0j5hW23MyZVwnkRJyOyFXiB-MJVLI7JJMuFKx1qmakmHRda62JtS-pb6im_UqelhsaPDUIAIixaGwQzAt-AFpAa5uxsiCQlWNmN3TuqWGWr_zfTgswD0GaGpL3dCNAPT7sIPDjTh23ZgDbcBrclEZh3BzqjPy_rh6Wz5H69enl-ViHdlYsxDFvDCsLJkpksyUCjKruE0157FMIauSVLFCC5uwkoPKbMJVbEttRJkZw6Qq-IzcHfd2vf8cAEPe1GjBueM7OWeSp5KxUemMqOOo7T1iD1Xe9XVj-n0es_xHev5fen6UPqK3p5ShaKD8A38t82-l9IcZ</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Ceccarelli, Fulvia</creator><creator>Picciariello, Licia</creator><creator>Natalucci, Francesco</creator><creator>Moretti, Valeria</creator><creator>Spinelli, Francesca Romana</creator><creator>Alessandri, Cristiano</creator><creator>Conti, Fabrizio</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240701</creationdate><title>Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients</title><author>Ceccarelli, Fulvia ; Picciariello, Licia ; Natalucci, Francesco ; Moretti, Valeria ; Spinelli, Francesca Romana ; Alessandri, Cristiano ; Conti, Fabrizio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c190t-13ba0dd0ab27ad8e7c83c4933164e7f2480b95c20d3e87c2381cd9a5d7aa068b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ceccarelli, Fulvia</creatorcontrib><creatorcontrib>Picciariello, Licia</creatorcontrib><creatorcontrib>Natalucci, Francesco</creatorcontrib><creatorcontrib>Moretti, Valeria</creatorcontrib><creatorcontrib>Spinelli, Francesca Romana</creatorcontrib><creatorcontrib>Alessandri, Cristiano</creatorcontrib><creatorcontrib>Conti, Fabrizio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ceccarelli, Fulvia</au><au>Picciariello, Licia</au><au>Natalucci, Francesco</au><au>Moretti, Valeria</au><au>Spinelli, Francesca Romana</au><au>Alessandri, Cristiano</au><au>Conti, Fabrizio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>42</volume><issue>7</issue><spage>1491</spage><pages>1491-</pages><issn>0392-856X</issn><issn>1593-098X</issn><eissn>1593-098X</eissn><abstract>To assess the efficacy of subcutaneous (sc) belimumab (BLM) by the application of SLE-DAS in a monocentric SLE cohort. We evaluated SLE patients treated with sc BLM from March 2019. Disease activity has been assessed by SLEDAI-2k, SLE-DAS and PGA (Physician Global Assessment) in all the established time-points [baseline (T0), after 1 (T1), 3 (T3), 6 (T6) and 12 (T12) months]. Furthermore, we applied and compared the achievement of remission according to SLE-DAS values (SLEDAS ≤2.08 + PDN ≤5mg/daily) and DORIS definition (clinical SLEDAI- 2k=0 + PGA&lt;0.5 + antimalarial treatment, PDN≤5mg/daily, stable immunosuppressive treatment). We enrolled 86 patients [M/F 5/81, median age 48 years (IQR 17.5), median disease duration 166 months (IQR 216)]. At baseline, median values of SLEDA-2k and SLE-DAS were 6 (IQR 4) and 5.77 (IQR 4.33), respectively, and they significantly correlated (r=0.719, CI 95% 0.586-0.815, p&lt;0.0001). Median duration of treatment was 14 months (IQR 20). We found a significant reduction of SLEDAI-2k and SLE-DAS already at T1, maintained in the subsequent time-points (p&lt;0.0001). At T12, a remission state was achieved by 60.4% of patients according to SLE-DAS definition and by 62.3% according to the DORIS definition. Both definitions of remission have demonstrated an agreement of 84%, with a Cohen's kappa equal to 0.6. In this study we applied SLE-DAS to assess the efficacy of sc BLM, by analysing its over-time changes and by comparing its performance with SLEDAI-2k. Indeed, our results suggest the usefulness of this new activity index in a real-life setting.</abstract><cop>Italy</cop><pmid>38819948</pmid><doi>10.55563/clinexprheumatol/l5976o</doi></addata></record>
fulltext fulltext
identifier ISSN: 0392-856X
ispartof Clinical and experimental rheumatology, 2024-07, Vol.42 (7), p.1491
issn 0392-856X
1593-098X
1593-098X
language eng
recordid cdi_proquest_miscellaneous_3063460056
source Alma/SFX Local Collection
title Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A49%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Application%20of%20SLE-DAS%20to%20assess%20subcutaneous%20belimumab%20efficacy%20in%20a%20cohort%20of%20systemic%20lupus%20erythematosus%20patients&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Ceccarelli,%20Fulvia&rft.date=2024-07-01&rft.volume=42&rft.issue=7&rft.spage=1491&rft.pages=1491-&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/10.55563/clinexprheumatol/l5976o&rft_dat=%3Cproquest_cross%3E3063460056%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3063460056&rft_id=info:pmid/38819948&rfr_iscdi=true